Literature DB >> 31429907

Natural History and Evolution of Anti-Interferon-γ Autoantibody-Associated Immunodeficiency Syndrome in Thailand and the United States.

Gloria H Hong1, Ana M Ortega-Villa2, Sally Hunsberger2, Ploenchan Chetchotisakd3, Siriluck Anunnatsiri3, Piroon Mootsikapun3, Lindsey B Rosen1, Christa S Zerbe1, Steven M Holland1.   

Abstract

BACKGROUND: The natural history of anti-interferon-γ (IFN-γ) autoantibody-associated immunodeficiency syndrome is not well understood.
METHODS: Data of 74 patients with anti-IFN-γ autoantibodies at Srinagarind Hospital, Thailand, were collected annually (median follow-up duration, 7.5 years). Annual data for 19 patients and initial data for 4 patients with anti-IFN-γ autoantibodies at the US National Institutes of Health were collected (median follow-up duration, 4.5 years). Anti-IFN-γ autoantibody levels were measured in plasma samples.
RESULTS: Ninety-one percent of US patients were of Southeast Asian descent; there was a stronger female predominance (91%) in US than Thai (64%) patients. Mycobacterium abscessus (34%) and Mycobacterium avium complex (83%) were the most common nontuberculous mycobacteria in Thailand and the United States, respectively. Skin infections were more common in Thailand (P = .001), whereas bone (P < .0001), lung (P = .002), and central nervous system (P = .03) infections were more common in the United States. Twenty-four percent of Thai patients died, most from infections. None of the 19 US patients with follow-up data died. Anti-IFN-γ autoantibody levels decreased over time in Thailand (P < .001) and the United States (P = .017), with either cyclophosphamide (P = .01) or rituximab therapy (P = .001).
CONCLUSIONS: Patients with anti-IFN-γ autoantibodies in Thailand and the United States had distinct demographic and clinical features. While titers generally decreased with time, anti-IFN-γ autoantibody disease had a chronic clinical course with persistent infections and death. Close long-term surveillance for new infections is recommended. Published by Oxford University Press for the Infectious Diseases Society of America 2019.

Entities:  

Keywords:  adult-onset immunodeficiency; anti-interferon-γ autoantibodies; anticytokine autoantibodies; disseminated nontuberculous mycobacterial infection; opportunistic infection

Mesh:

Substances:

Year:  2020        PMID: 31429907      PMCID: PMC7312243          DOI: 10.1093/cid/ciz786

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  37 in total

Review 1.  Host susceptibility to non-tuberculous mycobacterial infections.

Authors:  Un-In Wu; Steven M Holland
Journal:  Lancet Infect Dis       Date:  2015-06-03       Impact factor: 25.071

2.  Recurrence of disseminated Mycobacterium avium complex disease in a patient with anti-gamma interferon autoantibodies by reinfection.

Authors:  Tomoyasu Nishimura; Yukiko Fujita-Suzuki; Makoto Yonemaru; Kiyofumi Ohkusu; Takuro Sakagami; Stephen M Carpenter; Yoshihito Otsuka; Ho Namkoong; Ikuya Yano; Naoki Hasegawa
Journal:  J Clin Microbiol       Date:  2015-02-04       Impact factor: 5.948

3.  Practical issues in using generalized estimating equations for inference on transitions in longitudinal data: What is being estimated?

Authors:  Joe Bible; Paul S Albert; Bruce G Simons-Morton; Danping Liu
Journal:  Stat Med       Date:  2018-11-08       Impact factor: 2.373

4.  Clinical Significance of Interferon-γ Neutralizing Autoantibodies Against Disseminated Nontuberculous Mycobacterial Disease.

Authors:  Ami Aoki; Takuro Sakagami; Kazutaka Yoshizawa; Kenjiro Shima; Mio Toyama; Yoshinari Tanabe; Hiroshi Moro; Nobumasa Aoki; Satoshi Watanabe; Toshiyuki Koya; Takashi Hasegawa; Kozo Morimoto; Atsuyuki Kurashima; Yoshihiko Hoshino; Bruce C Trapnell; Toshiaki Kikuchi
Journal:  Clin Infect Dis       Date:  2018-04-03       Impact factor: 9.079

5.  Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infections.

Authors:  Smita Y Patel; Li Ding; Margaret R Brown; Larry Lantz; Ted Gay; Stuart Cohen; Lenna A Martyak; Bernard Kubak; Steven M Holland
Journal:  J Immunol       Date:  2005-10-01       Impact factor: 5.422

Review 6.  Immunodeficiency secondary to anticytokine autoantibodies.

Authors:  Sarah K Browne; Steven M Holland
Journal:  Curr Opin Allergy Clin Immunol       Date:  2010-12

7.  Anti-interferon-gamma autoantibody in a patient with disseminated Mycobacterium avium complex.

Authors:  Toshiyuki Koya; Chikako Tsubata; Hiroshi Kagamu; Ken-ichi Koyama; Masachika Hayashi; Katsuhiro Kuwabara; Takui Itoh; Yoshinari Tanabe; Toshinori Takada; Fumitake Gejyo
Journal:  J Infect Chemother       Date:  2009-04-25       Impact factor: 2.211

8.  Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma.

Authors:  Beate Kampmann; Cheryl Hemingway; Alick Stephens; Robert Davidson; Anna Goodsall; Suzanne Anderson; Mark Nicol; Elisabeth Schölvinck; David Relman; Simon Waddell; Paul Langford; Brian Sheehan; Lynn Semple; Katalin A Wilkinson; Robert J Wilkinson; Stanley Ress; Martin Hibberd; Michael Levin
Journal:  J Clin Invest       Date:  2005-08-25       Impact factor: 14.808

9.  Disseminated Mycobacterium genavense Infection in Patient with Adult-Onset Immunodeficiency.

Authors:  Takanori Asakura; Ho Namkoong; Takuro Sakagami; Naoki Hasegawa; Kiyofumi Ohkusu; Akira Nakamura
Journal:  Emerg Infect Dis       Date:  2017-07       Impact factor: 6.883

10.  Epidemiology of and risk factors for extrapulmonary nontuberculous mycobacterial infections in Northeast Thailand.

Authors:  Irin Kham-Ngam; Ploenchan Chetchotisakd; Pimjai Ananta; Prajaub Chaimanee; Phuangphaka Sadee; Wipa Reechaipichitkul; Kiatichai Faksri
Journal:  PeerJ       Date:  2018-08-16       Impact factor: 2.984

View more
  18 in total

1.  Clinicopathological Manifestations and Immune Phenotypes in Adult-Onset Immunodeficiency with Anti-interferon-γ Autoantibodies.

Authors:  Yi-Chun Chen; Shao-Wen Weng; Jing-Ya Ding; Chen-Hsiang Lee; Cheng-Lung Ku; Wen-Chi Huang; Huey-Ling You; Wan-Ting Huang
Journal:  J Clin Immunol       Date:  2022-01-28       Impact factor: 8.317

2.  Pathogenic autoantibodies to IFN-γ act through the impedance of receptor assembly and Fc-mediated response.

Authors:  Han-Po Shih; Jing-Ya Ding; Junel Sotolongo Bellón; Yu-Fang Lo; Pei-Han Chung; He-Ting Ting; Jhan-Jie Peng; Tsai-Yi Wu; Chia-Hao Lin; Chia-Chi Lo; You-Ning Lin; Chun-Fu Yeh; Jiun-Bo Chen; Ting-Shu Wu; Yuag-Meng Liu; Chen-Yen Kuo; Shang-Yu Wang; Kun-Hua Tu; Chau Yee Ng; Wei-Te Lei; Yu-Huan Tsai; Jou-Han Chen; Ya-Ting Chuang; Jing-Yi Huang; Félix A Rey; Hung-Kai Chen; Tse-Wen Chang; Jacob Piehler; Chih-Yu Chi; Cheng-Lung Ku
Journal:  J Exp Med       Date:  2022-07-14       Impact factor: 17.579

3.  Sweet's Syndrome Accompanied by Coinfection with Multiple Pathogens and Disseminated Mycobacterium phlei Infection Presenting with Osteolytic Destruction During 12 Years of Follow-Up: A Rare Case Report.

Authors:  Mengxin Tang; Mianluan Pan; Ye Qiu; Jie Huang; Wen Zeng; Jianquan Zhang
Journal:  Infect Drug Resist       Date:  2022-05-10       Impact factor: 4.177

Review 4.  Anticytokine autoantibodies: Autoimmunity trespassing on antimicrobial immunity.

Authors:  Aristine Cheng; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2022-01       Impact factor: 14.290

5.  Daratumumab (Anti-CD38) for Treatment of Disseminated Nontuberculous Mycobacteria in a Patient With Anti-Interferon-γ Autoantibodies.

Authors:  Sebastian Ochoa; Li Ding; Samantha Kreuzburg; Jennifer Treat; Steven M Holland; Christa S Zerbe
Journal:  Clin Infect Dis       Date:  2021-06-15       Impact factor: 9.079

Review 6.  Minireview: Insights into anti-interferon-γ autoantibodies.

Authors:  Kriangkrai Chawansuntati; Kritsadee Rattanathammethee; Jiraprapa Wipasa
Journal:  Exp Biol Med (Maywood)       Date:  2021-01-11

7.  Talaromyces marneffei Detected in the Peripheral Blood Smear of an Immunocompetent Individual.

Authors:  Hirokazu Kuroda; Hiroaki Nishioka
Journal:  Am J Trop Med Hyg       Date:  2022-04-11       Impact factor: 3.707

8.  Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies.

Authors:  Joseph M Rocco; Lindsey B Rosen; Gloria H Hong; Jennifer Treat; Samantha Kreuzburg; Steven M Holland; Christa S Zerbe
Journal:  J Transl Autoimmun       Date:  2021-05-04

9.  Treatment Dilemmas in Disseminated Nontuberculous Mycobacterial Infections With Interferon-gamma Autoantibodies.

Authors:  Elizabeth M King; Victoria K Weaver; Mary H Kestler
Journal:  Open Forum Infect Dis       Date:  2021-06-23       Impact factor: 3.835

10.  Clinical findings of Talaromyces marneffei infection among patients with anti-interferon-γ immunodeficiency: a prospective cohort study.

Authors:  Zhao-Ming Chen; Zheng-Tu Li; Wei-Jie Guan; Yang-Qing Zhan; Shao-Qiang Li; Ye Qiu; Zi-Ying Lei; Hua Zhou; Sheng Lin; Xinni Wang; Zhun Li; Feng Yang; Wen Zeng; Ye Lin; Jing Liu; Jian-Quan Zhang; Feng Ye
Journal:  BMC Infect Dis       Date:  2021-06-19       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.